Evidence map›Paper›PMID 31938827›Full record

ReviewIntensive care medicine2020

Clostridioides difficile (formerly Clostridium difficile) infection in the critically ill: an expert statement.

Massimo Antonelli, Ignacio Martin-Loeches, George Dimopoulos, Antonio Gasbarrini, Maria Sole Vallecoccia

Abstract readReview
PubMed Publisher
In one paragraph

Review in Intensive care medicine, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed, 1 pooled it
0.4field-weighted citation impact, top 25% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 1 synthesis or guideline pooled it, 27 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Healthcare-AssociatedMicroorganisms · 2025
    Article
  4. Frontiers in cellular and infection microbiology · 2025
    Article
  5. Article
  6. Article
  7. The management ofMedicine and pharmacy reports · 2024
    Review
  8. Article
  9. Traditional Chinese medicine against COVID-19: Role of the gut microbiota.Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie · 2022
    Review
  10. Review
  11. Review
  12. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 3 institutions in 4 countries.

Massimo AntonelliDepartment of Anesthesiology, Intensive Care and Emergency Medicine, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy. massimo.antonelli@unicatt.it.ORCID 0000-0003-3007-1670
Ignacio Martin-LoechesDepartment of Intensive Care Medicine, Multidisciplinary Intensive Care Research Organization (MICRO), St. James's Hospital, St James Street, Dublin 8, Dublin, Ireland.ORCID 0000-0002-5834-4063
George DimopoulosCritical Care Department, ATTIKON University Hospital, Medical School, National and Kapodistrian University of Athens, Athens, Greece.ORCID 0000-0002-3784-3103
Antonio GasbarriniUniversità Cattolica del Sacro Cuore, Rome, Italy.ORCID 0000-0002-7278-4823
Maria Sole VallecocciaDepartment of Anesthesiology, Intensive Care and Emergency Medicine, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy.ORCID 0000-0003-4493-7447
Università Cattolica del Sacro Cuore · ITNational and Kapodistrian University of Athens · GRSt. James's Hospital · IE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Clostridioides difficile (formerly Clostridium difficile) infection (CDI) represents a worrisome condition, often underestimated, with severe clinical presentations, frequently requiring intensive care unit (ICU) admission. The aim of the present expert statement was to give an overview of the management of CDI in critically ill patients, for whom CDI represents a redoubtable problem, in large part related to the use and abuse of antibiotics. The available knowledge about pathophysiology, risk factors, diagnosis and treatment concerning critical care patients affected by CDI has been reviewed, even though most of the existing information come from studies performed outside the ICU and the evidence on several issues in this specific context is scarce. The adoption of potential preventive and therapeutic strategies aimed to stem the phenomenon were discussed, including the faecal microbiota transplantation. This possibility could represent a highly interesting option in critically ill patients, but current evidence is limited and future well designed studies are needed. A special insight on the specific challenges that the ICU physicians may face caring for the critically ill patients with CDI was also proposed.

Indexed as

Anti-Bacterial AgentsClostridioides difficileClostridium InfectionsCross InfectionFecal Microbiota TransplantationHumansInfection ControlIntensive Care UnitsRisk FactorsTomography, X-Ray ComputedAnti-Bacterial AgentsBurden of Clostridioides difficile infectionClostridioides difficileClostridium difficileCritically ill patientsFecal microbiota transplantationTreatment

Identifiers

PMID31938827
OpenAlexW3000711074

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.